1. Home
  2. CTV vs MRSN Comparison

CTV vs MRSN Comparison

Compare CTV & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTV
  • MRSN
  • Stock Information
  • Founded
  • CTV 2007
  • MRSN 2001
  • Country
  • CTV United States
  • MRSN United States
  • Employees
  • CTV N/A
  • MRSN N/A
  • Industry
  • CTV Advertising
  • MRSN Biotechnology: Pharmaceutical Preparations
  • Sector
  • CTV Consumer Discretionary
  • MRSN Health Care
  • Exchange
  • CTV Nasdaq
  • MRSN Nasdaq
  • Market Cap
  • CTV 279.6M
  • MRSN 252.0M
  • IPO Year
  • CTV N/A
  • MRSN 2017
  • Fundamental
  • Price
  • CTV $3.07
  • MRSN $1.89
  • Analyst Decision
  • CTV Hold
  • MRSN Buy
  • Analyst Count
  • CTV 3
  • MRSN 6
  • Target Price
  • CTV $2.83
  • MRSN $6.00
  • AVG Volume (30 Days)
  • CTV 5.4M
  • MRSN 1.1M
  • Earning Date
  • CTV 11-12-2024
  • MRSN 11-13-2024
  • Dividend Yield
  • CTV N/A
  • MRSN N/A
  • EPS Growth
  • CTV N/A
  • MRSN N/A
  • EPS
  • CTV N/A
  • MRSN N/A
  • Revenue
  • CTV $151,557,000.00
  • MRSN $34,837,000.00
  • Revenue This Year
  • CTV $9.64
  • MRSN N/A
  • Revenue Next Year
  • CTV $10.07
  • MRSN N/A
  • P/E Ratio
  • CTV N/A
  • MRSN N/A
  • Revenue Growth
  • CTV 12.30
  • MRSN N/A
  • 52 Week Low
  • CTV $1.25
  • MRSN $1.22
  • 52 Week High
  • CTV $3.09
  • MRSN $6.28
  • Technical
  • Relative Strength Index (RSI)
  • CTV 78.42
  • MRSN 42.16
  • Support Level
  • CTV $3.05
  • MRSN $1.93
  • Resistance Level
  • CTV $3.09
  • MRSN $2.81
  • Average True Range (ATR)
  • CTV 0.02
  • MRSN 0.24
  • MACD
  • CTV -0.03
  • MRSN -0.05
  • Stochastic Oscillator
  • CTV 65.17
  • MRSN 7.79

About CTV Innovid Corp.

Innovid Corp is a software platform that provides ad serving, measurement and optimization creative services for the creation, delivery, and measurement of TV ads across connected TV, mobile TV and desktop TV environments to advertisers, publishers and media agencies. It is engaged in ad serving, measurement and creative services. It operates in U.S., Canada, EMEA, APAC and LATAM, out of which it derives maximum revenue from U.S.

About MRSN Mersana Therapeutics Inc.

Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.

Share on Social Networks: